Bone marrow microenvironment signatures associate with patient survival after guadecitabine and atezolizumab therapy in HMA-resistant MDS.
Jang HJ, Urrutia G, Orskov AD, Kim HJ, Nelson SA, Nguyen AV, Lee H, Burgos RS, Johnson BK, Wegener M, Becker K, Adams M, Sheridan R, Ramjan ZH, Givan SA, Zebley CC, Youngblood BA, Issa JJ, Topper MJ, Baylin SB, Baer MR, Triche TJ, O'Connell CL, Gronbaek K, Jones PA.
Jang HJ, et al. Among authors: jones pa.
bioRxiv [Preprint]. 2024 Nov 11:2024.11.08.622670. doi: 10.1101/2024.11.08.622670.
bioRxiv. 2024.
PMID: 39605731
Free PMC article.
Preprint.